R. Lescarbeau

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”

T. Barnes, R. Lescarbeau, Brad Murray, 2018, Nature Methods.

Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

David A. Drubin, D. Laifenfeld, A. V. Van Hooser, 2015, BMC Medical Genomics.

In Vitro Model of Metastasis to Bone Marrow Mediates Prostate Cancer Castration Resistant Growth through Paracrine and Extracellular Matrix Factors

D. Kaplan, C. Werner, R. Lescarbeau, 2012, PloS one.

CRISPR/Cas9 Gene-Edited Hematopoietic Stem Cell Therapy for Sickle Cell Disease

Jennifer L. Snead, M. Curran, C. Mickanin, 2017 .

A reanalysis of Schaefer et al. does not indicate extensive CRISPR/Cas9 mediated off-target editing events

T. Barnes, R. Lescarbeau, Brad Murray, 2017, bioRxiv.

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.

W. Harrington, William E. Salomon, L. Shaw, 2018, Cell reports.

Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

David A. Drubin, D. Laifenfeld, D. de Graaf, 2015, BMC Medical Genomics.

Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling

David L Kaplan, D. Kaplan, R. Lescarbeau, 2014, BMC Cancer.